J Korean Med Sci.  2009 Aug;24(4):567-570. 10.3346/jkms.2009.24.4.567.

Predictive Factors Associated with the Reversibility of Post-transplantation Diabetes Mellitus Following Liver Transplantation

• Ahn HY
• Cho YM
• Yi NJ
• Suh KS
• Lee KU
• Park KS
• Kim SY
• Lee HK

• KMID: 1779185
• DOI: http://doi.org/10.3346/jkms.2009.24.4.567

Abstract

Post-transplantation diabetes mellitus (PTDM) is reversible in a considerable number of patients. We examined the prevalence and predictive factors of transient PTDM following liver transplantation. Forty-two of 74 PTDM patients showed the clinical features of transient PTDM. Compared with the persistent PTDM patients, they were characterized by younger age at the time of transplantation (49+/-7 vs. 53+/-8 yr, P<0.05), longer time before the development of PTDM (44+/-59 vs. 13+/-20 days, P<0.05), lower rate of hepatitis c virus seropositivity (0.0 vs. 9.4%, P<0.05), and use of mycophenolate mofetil (59.5 vs. 28.1%, P<0.05). Among these risk factors, age at the time of transplantation is the single independent predictive factor associated with the reversibility of PTDM.

Keyword

Diabetes Mellitus; Liver Transplantation

MeSH Terms

Adult
Age Factors
Diabetes Mellitus/diagnosis/*epidemiology
Female
Hepacivirus/isolation & purification
Humans
*Liver Transplantation
Male
Middle Aged
Multivariate Analysis
Mycophenolic Acid/analogs & derivatives/metabolism
Predictive Value of Tests
Prevalence
Risk Factors

Reference

1. Moon JI, Barbeito R, Faradji RN, Gaynor JJ, Tzakis AG. Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation: long-term follow up. Transplantation. 2006. 82:1625–1628.

2. Khalili M, Lim JW, Bass N, Ascher NL, Roberts JP, Terrault NA. New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. Liver Transpl. 2004. 10:349–355.

3. Marchetti P. New-onset diabetes after liver transplantation: from pathogenesis to management. Liver Transpl. 2005. 11:612–620.

4. Shapiro R, Scantlebury VP, Jordan ML, Vivas C, Gritsch HA, McCauley J, Fung JJ, Hakala TR, Simmons RL, Starzl TE. Reversibility of tacrolimus-induced posttransplant diabetes: an illustrative case and review of the literature. Transplant Proc. 1997. 29:2737–2738.

5. Davidson J, Wilkinson A, Dantal J, Dotta F, Haller H, Hernandez D, Kasiske BL, Kiberd B, Krentz A, Legendre C, Marchetti P, Markell M, van der Woude FJ, Wheeler DC. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation. 2003. 75(10 Suppl):S3–S24.

6. Cho YM, Park KS, Jung HS, Jeon HJ, Ahn C, Ha J, Kim SJ, Rhee BD, Kim SY, Lee HK. High incidence of tacrolimus-associated posttransplantation diabetes in the Korean renal allograft recipients according to American Diabetes Association criteria. Diabetes Care. 2003. 26:1123–1128.

7. Hur KY, Kim MS, Kim YS, Kang ES, Nam JH, Kim SH, Nam CM, Ahn CW, Cha BS, Kim SI, Lee HC. Risk factors associated with the onset and progression of posttransplantation diabetes in renal allograft recipients. Diabetes Care. 2007. 30:609–615.

8. AlDosary AA, Ramji AS, Elliott TG, Sirrs SM, Thompson DM, Erb SR, Steinbrecher UP, Yoshida EM. Post-liver transplantation diabetes mellitus: an association with hepatitis C. Liver Transpl. 2002. 8:356–361.

9. Delgado-Borrego A, Casson D, Schoenfeld D, Somsouk M, Terella A, Jordan SH, Bhan A, Baid S, Cosimi AB, Pascual M, Chung RT. Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. Transplantation. 2004. 77:703–710.

10. Masini M, Campani D, Boggi U, Menicagli M, Funel N, Pollera M, Lupi R, Del Guerra S, Bugliani M, Torri S, Del Prato S, Mosca F, Filipponi F, Marchetti P. Hepatitis C virus infection and human pancreatic beta-cell dysfunction. Diabetes Care. 2005. 28:940–941.